Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain

SARS CoV-2 antibody assays measure antibodies against the viral nucleoprotein (NP) or spike protein. The study examined if testing of antibodies against both antigens increases the diagnostic sensitivity. Sera (N=98) from infected individuals were tested with ELISAs based on the NP, receptor-binding...

Descripción completa

Detalles Bibliográficos
Autores principales: Reiners, Nina, Schnurra, Carolin, Trawinski, Henning, Kannenberg, Judith, Hermsdorf, Thomas, Aebischer, Andrea, Schöneberg, Torsten, Reiche, Sven, Jassoy, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175097/
https://www.ncbi.nlm.nih.gov/pubmed/34085159
http://dx.doi.org/10.1007/s10096-021-04284-5
_version_ 1783702987153080320
author Reiners, Nina
Schnurra, Carolin
Trawinski, Henning
Kannenberg, Judith
Hermsdorf, Thomas
Aebischer, Andrea
Schöneberg, Torsten
Reiche, Sven
Jassoy, Christian
author_facet Reiners, Nina
Schnurra, Carolin
Trawinski, Henning
Kannenberg, Judith
Hermsdorf, Thomas
Aebischer, Andrea
Schöneberg, Torsten
Reiche, Sven
Jassoy, Christian
author_sort Reiners, Nina
collection PubMed
description SARS CoV-2 antibody assays measure antibodies against the viral nucleoprotein (NP) or spike protein. The study examined if testing of antibodies against both antigens increases the diagnostic sensitivity. Sera (N=98) from infected individuals were tested with ELISAs based on the NP, receptor-binding domain (RBD), or both proteins. The AUROCs were 0.958 (NP), 0.991 (RBD), and 0.992 (NP/RBD). The RBD- and NP/RBD-based ELISAs showed better performance than the NP-based assay. Simultaneous testing for antibodies against NP and RBD increased the number of true and false positives. If maximum diagnostic sensitivity is required, the NP/RBD-based ELISA is preferable. Otherwise, the RBD-based ELISA is sufficient. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10096-021-04284-5.
format Online
Article
Text
id pubmed-8175097
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-81750972021-06-04 Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain Reiners, Nina Schnurra, Carolin Trawinski, Henning Kannenberg, Judith Hermsdorf, Thomas Aebischer, Andrea Schöneberg, Torsten Reiche, Sven Jassoy, Christian Eur J Clin Microbiol Infect Dis Brief Report SARS CoV-2 antibody assays measure antibodies against the viral nucleoprotein (NP) or spike protein. The study examined if testing of antibodies against both antigens increases the diagnostic sensitivity. Sera (N=98) from infected individuals were tested with ELISAs based on the NP, receptor-binding domain (RBD), or both proteins. The AUROCs were 0.958 (NP), 0.991 (RBD), and 0.992 (NP/RBD). The RBD- and NP/RBD-based ELISAs showed better performance than the NP-based assay. Simultaneous testing for antibodies against NP and RBD increased the number of true and false positives. If maximum diagnostic sensitivity is required, the NP/RBD-based ELISA is preferable. Otherwise, the RBD-based ELISA is sufficient. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10096-021-04284-5. Springer Berlin Heidelberg 2021-06-04 2021 /pmc/articles/PMC8175097/ /pubmed/34085159 http://dx.doi.org/10.1007/s10096-021-04284-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Report
Reiners, Nina
Schnurra, Carolin
Trawinski, Henning
Kannenberg, Judith
Hermsdorf, Thomas
Aebischer, Andrea
Schöneberg, Torsten
Reiche, Sven
Jassoy, Christian
Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain
title Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain
title_full Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain
title_fullStr Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain
title_full_unstemmed Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain
title_short Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain
title_sort performance of a sars cov-2 antibody elisa based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175097/
https://www.ncbi.nlm.nih.gov/pubmed/34085159
http://dx.doi.org/10.1007/s10096-021-04284-5
work_keys_str_mv AT reinersnina performanceofasarscov2antibodyelisabasedonsimultaneousmeasurementofantibodiesagainsttheviralnucleoproteinandreceptorbindingdomain
AT schnurracarolin performanceofasarscov2antibodyelisabasedonsimultaneousmeasurementofantibodiesagainsttheviralnucleoproteinandreceptorbindingdomain
AT trawinskihenning performanceofasarscov2antibodyelisabasedonsimultaneousmeasurementofantibodiesagainsttheviralnucleoproteinandreceptorbindingdomain
AT kannenbergjudith performanceofasarscov2antibodyelisabasedonsimultaneousmeasurementofantibodiesagainsttheviralnucleoproteinandreceptorbindingdomain
AT hermsdorfthomas performanceofasarscov2antibodyelisabasedonsimultaneousmeasurementofantibodiesagainsttheviralnucleoproteinandreceptorbindingdomain
AT aebischerandrea performanceofasarscov2antibodyelisabasedonsimultaneousmeasurementofantibodiesagainsttheviralnucleoproteinandreceptorbindingdomain
AT schonebergtorsten performanceofasarscov2antibodyelisabasedonsimultaneousmeasurementofantibodiesagainsttheviralnucleoproteinandreceptorbindingdomain
AT reichesven performanceofasarscov2antibodyelisabasedonsimultaneousmeasurementofantibodiesagainsttheviralnucleoproteinandreceptorbindingdomain
AT jassoychristian performanceofasarscov2antibodyelisabasedonsimultaneousmeasurementofantibodiesagainsttheviralnucleoproteinandreceptorbindingdomain

Ejemplares similares